Tobias Ruck

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies.

Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice.

Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS.

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis.

CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation.

TREK-King the Blood-Brain-Barrier.

Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo.

Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.

Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation.

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.

Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms.

The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.

CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance.

ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.

Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.

The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells.

Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function.

Skeletal muscle cells actively shape (auto)immune responses.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis.

K18.1 translates T cell receptor signals into thymic regulatory T cell development.

Mini-Review: Two Brothers in Crime - The Interplay of TRESK and TREK in Human Diseases.

Eculizumab versus rituximab in generalised myasthenia gravis.

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.

Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis.

Deficiency of the Two-Pore Potassium Channel KCNK9 Impairs Intestinal Epithelial Cell Survival and Aggravates Dextran Sodium Sulfate-Induced Colitis.

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019.

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany.

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study.

Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis.